PuSH - Publikationsserver des Helmholtz Zentrums München

Hoffmann, G.V.* ; Gottschlich, A.* ; Subklewe, M.* ; Kobold, S.

Novel approaches to CAR T cell target identification in acute myeloid leukemia.

Curr. Opin. Pharmacol. 82:102524 (2025)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Identifying safe and effective CAR T cell targets in acute myeloid leukemia (AML) is challenging due to the disease's complexity and overlap with normal hematopoiesis. This review highlights advances in target discovery for AML, emphasizing innovative approaches. Structural surfaceomics identifies tumor-specific protein conformations, while AI-driven single-cell RNA sequencing integrates multi-source data to pinpoint optimal targets. Refined cell surface capture technology maps the AML surfaceome without relying on predefined antibodies. These strategies enhance CAR T cell specificity and minimize off-tumor effects, offering promising pathways for safer and more effective AML treatments and broader cancer therapies.
Impact Factor
Scopus SNIP
Altmetric
4.200
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Stem-cells; Antibody; Therapy; Heterogeneity; Expression; Ozogamicin; Cultures; Cancer
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 1471-4892
e-ISSN 1471-4973
Quellenangaben Band: 82, Heft: , Seiten: , Artikelnummer: 102524 Supplement: ,
Verlag Elsevier
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-522100-001
Förderungen Bavarian Research Foundation (BAYCELLATOR)
Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer - Horizon 2020 programme of the European Union
German Cancer Aid
Wilhelm-Sander-Stiftung
Ernst Jung Stiftung
Institutional Strategy LMUexcellent of LMU Munich
Bavarian Ministry for Economical Affairs
Bundesministerium fur Bildung und Forschung
European Research Council
Deutsche Forschungsgemeinschaft (DFG)
Fritz-Bender Foundation
Monika-Kutzner Foundation for Cancer Research
Horizon 2020 programme of the European Union
Scopus ID 105003924259
PubMed ID 40311558
Erfassungsdatum 2025-05-11